Compare GOOS & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GOOS | CMPX |
|---|---|---|
| Founded | 1957 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 926.7M |
| IPO Year | 2016 | 2020 |
| Metric | GOOS | CMPX |
|---|---|---|
| Price | $10.99 | $5.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $12.60 | ★ $14.43 |
| AVG Volume (30 Days) | 506.8K | ★ 1.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.21 | N/A |
| Revenue Next Year | $5.16 | $830.89 |
| P/E Ratio | $75.22 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.73 | $1.33 |
| 52 Week High | $15.43 | $6.88 |
| Indicator | GOOS | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 36.57 | 41.68 |
| Support Level | $10.94 | $4.78 |
| Resistance Level | $14.45 | $5.86 |
| Average True Range (ATR) | 0.36 | 0.31 |
| MACD | -0.09 | -0.06 |
| Stochastic Oscillator | 13.91 | 25.87 |
Canada Goose Holdings Inc is a Canada-based company that designs, manufactures, distributes, and retails premium outerwear for men, women, and children. It operates business through three segments namely, Wholesale and Direct to Consumer (DTC), Other. The DTC segment, which is the key revenue driver, comprises sales through country-specific e-commerce platforms and its company-owned retail stores located in luxury shopping locations. The Wholesale segment comprises sales made to a mix of retailers and international distributors, who are partners that have exclusive rights to an entire market, and travel retail locations. Geographically, it has a presence in Canada, the United States, North America, Greater China, Asia, and Europe, the Middle East, and Africa.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.